NuVasive received FDA 510(k) clearance for the use of its Modulus Cervical interbody implant with a bone void filler, thus enhancing the company’s C360 portfolio.
Attrax Putty is reportedly the first synthetic bone graft substitute to receive FDA-cleared Indications for Use in thoracolumbar interbody fusion spacers. Subsequently published evidence clinically validated the combination of NuVasive’s Advanced Materials Science solutions, Modulus XLIF and Attrax Putty, as having clinical and economic advantages over traditional, non-porous interbody implants and premium-priced biologics.
NuVasive received FDA 510(k) clearance for the use of its Modulus Cervical interbody implant with a bone void filler, thus enhancing the company's C360 portfolio.
Attrax Putty is reportedly the first synthetic bone graft substitute to receive FDA-cleared Indications for Use in thoracolumbar interbody fusion spacers. Subsequently published...
NuVasive received FDA 510(k) clearance for the use of its Modulus Cervical interbody implant with a bone void filler, thus enhancing the company’s C360 portfolio.
Attrax Putty is reportedly the first synthetic bone graft substitute to receive FDA-cleared Indications for Use in thoracolumbar interbody fusion spacers. Subsequently published evidence clinically validated the combination of NuVasive’s Advanced Materials Science solutions, Modulus XLIF and Attrax Putty, as having clinical and economic advantages over traditional, non-porous interbody implants and premium-priced biologics.
Copy to clipboard 
